Education, EUGLOH, Research
SPOC MIRACIP: Management of immunorelated complication of cancer immunotherapy
… SPOC MIRACIP: Management of immunorelated complication of cancer immunotherapy SPOC MIRACIP: … are the most promising drugs, they are associated with side effects in around 70% of treated patients, such called … those of traditional cancer therapies, and typically have delayed onset and prolonged duration. Some of them can be …Published on: Thu 20/02/2025 - 15:07